Models incorporating chromatin modification data identify functionally important p53 binding sites by Lim, Ji-Hyun et al.
Models incorporating chromatin modification data
identify functionally important p53 binding sites
Ji-Hyun Lim1,2, Richard D. Iggo2,3,* and Daniel Barker1,*
1Sir Harold Mitchell Building, School of Biology, University of St Andrews, St Andrews, Fife, KY16 9TH, UK,
2School of Medicine, University of St Andrews, Fife, KY16 9TF, UK and 3INSERM U916, Bergonie Cancer
Institute, University of Bordeaux, 229 Cours de l’Argonne, 33076 Bordeaux, France
Received January 18, 2013; Revised March 19, 2013; Accepted March 21, 2013
ABSTRACT
Genome-wide prediction of transcription factor
binding sites is notoriously difficult. We have de-
veloped and applied a logistic regression approach
for prediction of binding sites for the p53 transcrip-
tion factor that incorporates sequence information
and chromatin modification data. We tested this by
comparison of predicted sites with known binding
sites defined by chromatin immunoprecipitation
(ChIP), by the location of predictions relative to
genes, by the function of nearby genes and by
analysis of gene expression data after p53 activa-
tion. We compared the predictions made by our
novel model with predictions based only on
matches to a sequence position weight matrix
(PWM). In whole genome assays, the fraction of
known sites identified by the two models was
similar, suggesting that there was little to be
gained from including chromatin modification data.
In contrast, there were highly significant and bio-
logically relevant differences between the two
models in the location of the predicted binding
sites relative to genes, in the function of nearby
genes and in the responsiveness of nearby genes
to p53 activation. We propose that these contradict-
ory results can be explained by PWM and ChIP
data reflecting primarily biophysical properties of
protein–DNA interactions, whereas chromatin
modification data capture biologically important
functional information.
INTRODUCTION
Two mechanisms have come to dominate our understand-
ing of gene regulation: binding of transcription factors to
short DNA sequences, and binding of microRNAs to short
RNA sequences. The primary information dictating the
choice of binding site in both cases lies in the genomic
DNA sequence. For microRNAs the detection problem
is relatively simple because the binding sites must lie some-
where within the transcript, and they typically lie within an
even smaller region spanning only a few hundreds or thou-
sands of bases in the untranslated regions of the mRNA.
For transcription factors, the problem is vastly more difﬁ-
cult because binding sites can lie over 1Mb from the gene
they regulate, although chromatin interaction analysis with
pair-end tag sequencing (ChIA-PET) data for oestrogen
receptor alpha (ER-a) suggest most binding sites are
located within 100 kb of the gene (1). Despite the difﬁculty,
genome-wide mapping of transcription factor binding sites
is fundamental to understanding gene regulation and it
remains an important goal in bioinformatics.
The p53 tumor suppressor gene (TP53) encodes a tran-
scription factor that binds directly to DNA and activates
transcription in response to a wide range of different
stresses (2–4). p53 is a critical defense against cancer,
and loss of p53 function through TP53 mutation occurs
in more than half of all human tumors (5). p53 target
genes are implicated in a wide range of functions of
which the best known are cell cycle control and cell
death (6). p53 binds to DNA as a dimer of dimers.
Each core domain dimer binds to a decamer that is
described by the palindromic regular expression pattern
[AG][AG][AG]C[AT][TA]G[TC][TC][TC] (7), where
‘[AG]’, for example, matches either of the two bases ‘A’
and ‘G’. A p53 response element (RE) typically contains
two decamers that are either directly adjacent or separated
by a spacer up to 13 bp in length or occasionally longer
(3,7).
As is typical for a transcription factor binding site, the
p53 binding motif is short and degenerate. In large
genomes, approximate matches to the motif are found in
extremely large numbers. From the point of view of pre-
dicting functional binding sites, most of these matches are
false positives. Despite decades of study covering a wide
range of different transcription factors, identiﬁcation of
binding sites purely on the basis of sequence has not
*To whom correspondence should be addressed. Tel: +44 1334 463598; Fax: +44 1334 463366; Email: db60@st-andrews.ac.uk
Correspondence may also be addressed to Richard Iggo. Tel: +33 5 56 33 04 23; Fax: +33 5 56 33 32 06; Email: r.iggo@bordeaux.unicancer.fr
5582–5593 Nucleic Acids Research, 2013, Vol. 41, No. 11 Published online 17 April 2013
doi:10.1093/nar/gkt260
 The Author(s) 2013. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial
re-use, please contact journals.permissions@oup.com
 at St A
ndrew
s U
niversity Library on July 30, 2013
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
yielded predictions that could plausibly be extrapolated to a
genome-wide scale. Hence, further progress in the ﬁeld will
almost certainly require the inclusion of additional types of
information to reduce the number of false-positive predic-
tions. Computational sequence-based approaches to
predict binding sites include position weight matrices
(PWMs) (8–16), hidden Markov models (17–19) and
support vector machines (20,21). Compared with a simple
regular expression, these more accurately represent the
extent of variation at speciﬁc base positions in the binding
sequence. However, the short length of the sequence still
leaves a large number of false positive predictions. One
promising approach for improved predictions is to
combine evidence from DNA sequence with evidence as
to whether the genomic location is ever likely to act as a
regulatory region (20,22,23). Chromatin architecture is a
critical regulator of transcription factor binding and
activity. Speciﬁc histone modifying enzymes recruited by
p53 directly affect gene expression (24,25). The two
histone arginine methyltransferases CARM1 and
PRMT1, which methylate Arg2, Arg17 and Arg26 of
histone H3 and Arg3 of histone H4, have been shown to
act as coactivators by directly interacting with p53 and its
associated cofactor p300 (24,26). Several groups have pre-
viously attempted to incorporate histone modiﬁcation data
into transcription factor binding site mapping algorithms.
Won et al. (23) developed a hidden Markov model–based
approach, combining sequence information with
chromatin immunoprecipitation sequencing (ChIP-seq)
signals of histone modiﬁcations at promoter and enhancer
regions to detect functional sequence patterns. Ernst et al.
(22) described a logistic regression-based method to arrive
at a ‘general binding preference’ for DNAon the basis of 29
input features, including the distance to nearest transcrip-
tional start site, information on conservation and levels of
histone modiﬁcations, followed by use of a PWM to predict
which speciﬁc transcription factor is involved. However,
despite success with several other transcription factors,
the authors found the ability of this method to predict
p53 binding sites was low (22).
In this article, we present a multiple logistic regression
approach that integrates DNA sequence information
and histone modiﬁcation data to model p53 binding on
a genome-wide scale. Unexpectedly, our combined-
evidence model shows similar performance to a
sequence-only (PWM) model in tests strictly limited to
DNA–protein interactions, but is much better at predict-
ing functionally important p53 binding sites.
MATERIALS AND METHODS
Data for training and testing
The set of 1757 p53 binding sites used to train and test our
binary logistic regression model contained 1422 sites from
Smeenk et al. (27), 327 sites from Wei et al. (28) and 8 sites
from Horvath et al. (29). To avoid redundancy, we deleted
123 sites from (27) because they were also present in (28).
The overlap between the two main data sources is analyzed
in Supplementary Table S1. To avoid overﬁtting when
building the model, we included eight validated p53
binding sites from (29) that differed from the known p53
consensus sequence (Supplementary Table S2). For the
ChIP-PET data (28), we extracted the hg17 coordinates
of all clusters with three or more overlapping DNA frag-
ments (PET-3+clusters) from UCSC (http://genome.ucsc.
edu) (30,31) viaMySQL (genome-mysql.cse.ucsc.edu). The
genome-wide ChIP-on-chip binding data were supplied
directly by the authors (27). Because these data were
based on NCBI36 coordinates, we mapped them to hg17
using nucleotide–nucleotide BLAST (32) with a database
of human genomic DNA from release 35 of Ensembl (33).
To determine the precise locations of binding sites
within ChIP-based binding regions, we scanned the
ChIP sequences for matches to PFM M01651 in the
TRANSFAC database (BioBase Corporation; www.
biobase-international.com/transcription-factor-binding-
sites). We split this 20-mer motif into two component half
sites, and searched both strands of the DNA for matches
to each half site using FIMO (34) in the MEME package
(35). Two decamer half sites were regarded as a match to
the full binding site if they were directly adjacent or
separated by a spacer of at most 13 bp. The score of a
full site was determined as the sum of the individual
scores for its half sites. The full site with the highest
score was selected to represent the p53 binding site
within the ChIP sequence.
The 1757 p53 binding sites were split into training and
testing sets. Half of the binding sites from each study were
randomly taken as positive training data and the remain-
ing half were used as positive test data. In addition, we
generated the same proportion of negative data for
training and testing. We generated the negative sites by
randomly selecting repeat-free regions from protein-
coding regions of exons within the human genome in
Ensembl release 35, on the assumption that p53 binding
sites are rare in coding exons (3). The length (bp) of spacer
between the two half sites of each negative sequence was
chosen using the ‘random_uniform_integer’ function in
the Math::Random Perl module to select an integer in
the range 0–13 with equal probability. Training and test
data are given in Supplementary Datasets S1 and S2.
Model input
The predictor variables considered in the combined-
evidence model are listed in Supplementary Table S3.
For the combined-evidence model, logistic regression
was used as our prediction method. This is suited to a
binary response (y=1 if a given site is a p53 binding
site; y=0 if a given site is not a p53 binding site) and
reports coefﬁcients for all predictors, allowing biological
interpretation.
Histone modiﬁcation ChIP-seq data for histone 3 lysine
4 monomethylation (H3K4me1), dimethylation
(H3K4me2) and trimethylation (H3K4me3) in the
HMEC, HUVEC, NHEK and NHLF cell strains and
for H3K4me2 and H3K4me3 in the HepG2 cell line
were obtained from ENCODE/Broad Institute via the
UCSC Genome Browser. All four cell strains and
the HepG2 cell line are known to express wild-type p53.
The coordinates of the 36 589 enhancers recently predicted
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via chromatin signatures (36) were downloaded from the
Ren Lab Web site. The hg18 coordinates of histone modi-
ﬁcations and enhancers were converted to hg17 coordin-
ates using the LiftOver tool on the UCSC Genome
Browser (http://genome.ucsc.edu/cgi-bin/hgLiftOver).
The primary structure-based predictors considered were
decamer1_score, representing FIMO score for ﬁrst half
site; decamer2_score, representing FIMO score for
second half site; pair_score, representing FIMO score for
the full binding site; and spacer, representing spacer
length. Preliminary analyses were performed using
binary and continuous encodings of these predictors.
The non-sequence predictors considered were in_enhancer,
representing full or partial overlap with enhancer chroma-
tin signatures, and in_H3K4me1, in_H3K4me2 and
in_H3K4me3, representing overlap with H3K4me1,
H3K4me2 and H3K4me3 signals, respectively. Non-
sequence predictors were encoded as binary variables
(1 for overlap and 0 for no overlap).
The sequence-only model used a single predictor, the
continuously encoded pair_score, obtained as for the
combined-evidence model. This is equivalent to using
the 20-mer PWM and allowing a zero-penalty gap of up
to 13 bp between bases 10 and 11.
Training and testing
To avoid difﬁculties with complete or quasi-complete sep-
aration or numerical problems in the standard generalized
linear model, which relies on maximum likelihood estima-
tion, we used penalized likelihood (Firth logistic regres-
sion), implemented in the ‘logistf’ function in the ‘logistf’
package (37,38) in R (39). We used backward elimination,
starting with a model that included the binary non-
sequence predictors and continuous encoding of the
primary structure-based predictors pair_score and spacer
with its quadratic term (Supplementary Table S3), and
sequentially removed the least important predictors (the
ones with the largest P values) until no further improve-
ment of the model could be achieved. The remaining pre-
dictor variables in the combined-evidence model had
individual P values that were less than or close to 0.05,
indicating some evidence of statistical signiﬁcance. The
ﬁnal combined-evidence model was compared with
the sequence-only model. We evaluated the quality of
the models using the testing dataset. The maximized sum
threshold (MST), which gave the best sensitivity (true
positive rate or recall) and speciﬁcity (true negative rate)
on the training dataset, was used as the cutoff for
categorizing the predictions obtained from the testing
dataset.
Location of genome-wide predictions
Starting at the ﬁrst position in the genomic sequence we
used a sliding window of size 20–33 bp to retrieve all pairs
of potential decameric sites separated by a spacer of 0–
13 bp. For each pair of such decameric sites in the human
genome, we estimated the probability of being a p53
binding site based on the combined-evidence model. We
identiﬁed the location of our predictions in the human
genome relative to Ensembl genes that are not single-exon
genes and grouped the binding sites into six categories:
intragenic (all introns and exons except the ﬁrst exon
and intron), ﬂanking the transcription start site (TSS)
(ﬁrst intron, ﬁrst exon and 5 kb upstream of TSS), 5 kb
downstream (5 kb downstream of last exon), 5–25 kb
downstream, 5–25 kb upstream and intergenic regions. A
distinction between protein coding region and untrans-
lated region was not made. The categories were based
on (27) with the exception that we did not merge 5–
25 kb downstream and 5–25 kb upstream regions
together as one classiﬁcation group. G tests were used to
compare the distribution of sets of predictions across these
genomic categories, between each prediction set and ex-
pectations from the proportions of the genome in each
category, between pairs of prediction sets, and between
positive training data and prediction sets.
The predicted p53 binding sites were assigned to their
nearest genes using the Ensembl Perl API (Ensembl
release 35). If a prediction was located within the
transcribed region of a gene, that gene was considered as
the nearest gene. If not within a transcribed region, the
prediction was determined to have two nearest genes, one
up- and one downstream, that overlapped the 150 kb
ﬂanking region at both the 50 and 30 ends of the prediction.
Those predictions that were >150 kb away from any gene
were regarded as having no nearest gene. Non-redundant
lists of unique nearest genes were functionally analyzed
using Gene Ontology (GO) ‘biological process’ categories
(40) and KEGG pathways (41). For given gene lists, stat-
istically enriched GO terms were detected using DAVID
(http://david.abcc.ncifcrf.gov) (42,43).
Gene set enrichment analysis of genome-wide predictions
To detect any tendency of binding sites predicted by the
two models to be in or near genes up- or downregulated by
p53, gene set enrichment analysis (GSEA) of a p53 acti-
vation experiment was performed. The HCT116 cell line
contains wild-type p53 and has been extensively used to
study gene expression changes following p53 activation.
The .cel ﬁles for an Affymetrix microarray experiment in
which HCT116 cells were treated with 5-ﬂuorouracil
(5FU) to activate p53 were downloaded from GEO, ac-
cession GSE36593 (44). The .cel ﬁles were normalized for
‘core’ transcripts with ‘rma’ in the ‘oligo’ package in R,
then differentially expressed genes were ranked by t stat-
istic generated by contrasting control with 5FU-treated
cells with the ‘limma’ package (45). GSEA plots were
created in R without weighting the step size by the t stat-
istic. To create the gene sets, the predictions from the
models were ordered by logit score (combined evidence)
or bit score (sequence only). To determine whether mean-
ingful predictions were concentrated at the top of the pre-
diction lists, progressively larger gene sets were tested, in
steps of 100 genes. To test the signiﬁcance of the GSEA
enrichment score, the gene ranking from limma was
permuted 100 000 times to generate a null distribution
for the enrichment scores, which was compared with the
observed enrichment using both a Normal assumption (Z
score) and a direct comparison with the empirical null
distribution (quantile).
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RESULTS
A logistic regression model to predict p53 binding sites
The ﬁnal reduced model using combined sources of
evidence includes the following continuous inputs: the
quality of the match to the p53 decamer RE expressed
as the sum of the PWM scores for the two constituent
decamers; and the spacer length between the decamers,
up to a maximum of 13 bp. We refer to these inputs as
pair_score.cont and spacer.cont, respectively. The ﬁnal
model also includes the following binary inputs, where 1
indicates overlap and 0 indicates no overlap:
monomethylation of lysine 4 in histone 3, in the NHLF
(in_NhlfH3K4me1) and NHEK (in_NhekH3K4me1)
cell strains; and trimethylation of lysine 4 in histone 3,
in the NHEK (in_NhekH3K4me3) and HUVEC
(in_HuvecH3K4me3) cell strains. Binary logistic regression
combines the inputs to create a logit score. The logit score
is a log likelihood ratio, positive when the model predicts a
region of the genome is a p53 binding site (y=1) and
negative when the model predicts a region is not a p53
binding site (y=0). The logit score may be converted to
a probability (46), with higher logit scores representing
higher probability that a region is a p53 binding site.
The logit score for the ﬁnal reduced model, using
combined evidence, is given as follows:
logit P y ¼ 1ð Þ½  ¼ 3:9932+0:8391pair score:cont
 1:5315spacer:cont
+0:1039spacer:cont2
+3:6782in NhlfH3K4me1
+5:6133in NhekH3K4me1
 7:0282in NhekH3K4me3
+5:9039in HuvecH3K4me3
ð1Þ
A Perl script to apply this model is provided as
Supplementary Script 1.
Positive coefﬁcients in the model indicate positive
evidence for a site being a functional p53 binding site.
Interestingly, one of the coefﬁcients for histone H3 K4
trimethylation in the model is negative, indicating that—
in the context of the model as a whole—penalizing these
sites improves performance. This makes sense because the
strongest signals for trimethylation of histone H3 K4 are
found at TSSs independently of p53. The other coefﬁcient
for H3 K4 trimethylation in the model is positive, presum-
ably because this histone mark is also found to a lesser
extent at enhancers.
Training and testing
The MST was used to choose the threshold at which to
evaluate the performance of the model on the training
and testing data. At a logit cutoff of 0.4422 (probability
cutoff of 0.6087938), the combined-evidence model
achieved a sensitivity of 0.9989, a speciﬁcity of 1 and an
area under the receiver operating characteristic curve
(AUC) of 0.9999974 for the training data. The correspond-
ing ﬁgures for the test data were sensitivity=0.9943, spe-
ciﬁcity=0.9932 and AUC=0.9994. In the test data, ﬁve
out of the 878 positive sites (including three of the sites
shown in Supplementary Table S2 that were included to
increase variability) and six out of the 878 negative sites
were misclassiﬁed by the combined-evidence model. At its
MST (bit-score cutoff 3.8731), the sequence-only model
achieved a sensitivity of 0.9989, speciﬁcity of 0.9966 and
AUC of 0.9999573 for the training data, and a sensitivity
of 0.9966, speciﬁcity of 0.9954 and AUC of 0.9995 for the
test data. Precision-recall plots also show high perform-
ance for both models, with both training and test data
(Figure 1). We conclude from this that there is no gain
from including additional predictors in the model when
dealing with a small dataset that is highly enriched in p53
binding sites.
Genome-wide prediction of p53 binding sites
It has been estimated that there may be 3000 functional p53
binding sites in the human genome (27). Allowing a binding
site to start at any base and including a spacer of length 0 to
13bp, a priori the number of sites in the human genome
where a binding site could potentially occur (which must be
at least considered when making computational predic-
tions) is the number of nucleotides in the genome multiplied
by 14, or 4 1010 potential binding sites. True binding
sites thus represent <1 in 107 potential sites. Identiﬁcation
of functional binding sites in the whole genome is thus far
more difﬁcult than in small preselected datasets because of
the vastly greater number of false positives expected at all
levels of sensitivity. For this reason, we suspected that the
difference in performance of the combined-evidence and
sequence-only models would be greater in genome-wide
analyses than in the test dataset. To evaluate the beneﬁt
of including modiﬁcation data, we used the sequence-only
and combined-evidence models to predict p53 binding at
levels of stringency chosen to give 300, 3000 and 30000
predicted sites. For each prediction method, we refer to
these three sets of predictions as the ‘stringent’, ‘intermedi-
ate’ and ‘large’ sets, respectively. The ‘large’ set was
expected to contain a large fraction of the true p53
binding sites in the genome, whereas the ‘stringent’ set
was used to ﬁnd out whether extreme scores would enrich
for the best sites. The thresholds (logit score) used for the
combined-evidence model were 30.9749, 27.1470 and
22.5783 for the stringent, intermediate and large sets, re-
spectively, yielding 305, 2999 and 30000 predicted binding
sites. The thresholds (bit score) used for the sequence-only
model were 24.7577, 21.6901 and 17.97233 for the stringent,
intermediate and large sets, respectively, yielding 305, 2998
and 30006 predicted binding sites. The sets of predictions
for each model are provided as Supplementary Material
(Supplementary Datasets S3–S8). The combined-evidence
model gives high scores for a range of ‘classic’ p53
binding sites (Supplementary Table S4).
As expected, the sequence logos of the p53 binding sites
predicted by both models closely resembled the known
p53 consensus, [AG][AG][AG]C[AT][TA]G[TC][TC][TC]
(Figure 2).
The combined model showed no strong single nucleo-
tide preferences other than for the invariant C or G in the
fourth and seventh base position in the decamers,
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corresponding to the fourth positions in the primary DNA
pentamers that bind to p53 protein monomers. In
contrast, the sequence-only model showed a preference
for G at the second position in the primary pentamers
and for AT in the middle of the decamers. Both models
showed a preference for no spacer between the decamers,
although this effect was stronger for the combined-
evidence model (Figure 3). The combined-evidence
Figure 1. Precision-recall curves for (A) the training data and (B) the test data, for the combined-evidence and sequence-only models. To distinguish
the performance of the two methods, the varying areas of the full plots on the left side (highlighted with a gray box) are re-plotted at higher
magniﬁcation (right side).
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Figure 2. Sequence logos for the predicted p53 binding sites. Combined-evidence model: (A) large set, (B) intermediate set and (C) stringent set of
predictions. Sequence-only model: (D) large set, (E) intermediate set and (F) stringent set of predictions. For clarity, spacers between the two
decamers were removed for generation of the logos. Any spacer would appear between bases 10 and 11. The logos were generated with the ‘seqLogo’
package for R.
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model includes spacer length as an input, and hence it is
expected to better match the training data in this respect
(Equation 1). Interestingly, the combined-evidence model
showed a progressive fall in the number of sites up to a
spacer length of eight base pairs, followed by an increase.
Recent structural studies explain the preference for having
no spacer (47). In the absence of a spacer, the p53 dimers
pack together with a much larger buried surface area and
form interdimer salt bridges between 180E and 181R in
helix 1. An increase in electrostatic potential induced by
minor groove narrowing at Hoogsteen base pairs further
improves binding through strengthening the interaction
with the positively charged 248R side chain. Early
studies showed that spacers of 5 or 15 bp reduced p53
binding and transactivation, whereas spacers of 10 bp
did not (48). This phasing behavior was interpreted as
indicating a preference for the core DNA binding
domain dimers within the p53 tetramer to be placed on
the same side of the DNA helix. Consistent with this, the
Smeenk et al. ChIP-on-chip study showed a greater abun-
dance of sites with spacers of length 10 bp than other
lengths in the range 2–13 bp (27) but most studies would
not support a role for phasing as a major constraint on
DNA binding [reviewed in (3)].
To test the quality of our genome-wide predictions, we
ﬁrst checked the degree of overlap with sites of p53
binding deﬁned experimentally by ChIP-on-chip (27) and
ChIP-PET (28). To avoid overestimating the degree of
overlap, binding sites present in the training set were
excluded from this comparison. For the ChIP-on-chip
data, the combined-evidence model discovered a higher
proportion of sites than the sequence-only model, at
each of the three sizes of prediction set (Table 1). The
ChIP-PET dataset (28) lists the number of PET tags per
site, a surrogate measure of DNA binding afﬁnity or
enhancer occupancy. With the intermediate prediction
sets, the models identiﬁed 41.10% (combined evidence)
or 38.04% (sequence only) of the ChIP-PET binding
sites; with the stringent sets, they identiﬁed 15.34%
(combined evidence) or 11.66% (sequence only) of the
ChIP-PET sites. Table 2 shows that sensitivity was
slightly better for sites in PET clusters with a greater
number of tags, but sites in the stringent set were not se-
lectively enriched for clusters with higher numbers of tags.
For the combined-evidence model to identify 90% of the
ChIP-PET sites, we estimate that a prediction set contain-
ing >1 000 000 predicted binding sites would be required
(Supplementary Table S6). The beneﬁt was slightly greater
for the ChIP-on-chip than for the ChIP-PET sites,
perhaps because of the larger number of ChIP-on-chip
than ChIP-PET sites used to train the model. Overall,
these results show curiously little gain in sensitivity from
inclusion of modiﬁcation and spacing data in the model.
This highlights the primacy of DNA sequence in
determining DNA binding by p53, even when modiﬁca-
tion data are included, but the failure of either model to
identify some sites indicates that binding to non-consensus
sequences, possibly bridged by another protein (49), may
be responsible for recruitment to a substantial number of
enhancers.
Location of predicted binding sites relative to genes
An ideal method would identify sites with the following
properties: they would differ from randomly chosen sites;
they would differ from sites predicted by less effective
methods; and they would resemble the sites in the
positive training dataset. To test these assumptions, the
genome was divided into six categories or regions:
intergenic, intragenic, ﬂanking the TSS, 5 kb downstream,
5–25 kb upstream and 5–25 kb downstream. The null
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Figure 3. Spacer length distribution of the sites predicted by the sequence-only model (light gray) and the combined-evidence model (dark gray) for
(A) large sets, (B) intermediate sets and (C) stringent sets of predictions, and for the full positive data (D).
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expectation for a model that predicted binding sites at
random is that the fraction of predictions in a category
should match the fraction of the genome in that category.
The overall assignment of binding sites to the six
categories departed from the null expectation for all three
sets of predictions made by both models. In general, there
was enrichment for genes and neighboring regions, and se-
lection against intergenic regions (Figure 4; Supplementary
Tables S7 and S8). For the combined-evidence model, the
departure from the null expectation was more extreme, with
far fewer predictions in intergenic regions than were made
by the sequence-only model (Figure 4). This difference
between the two models was statistically signiﬁcant (large
sets G=2722.46, 5 df, P< 2.2 1016; intermediate sets
G=218.81, P< 2.2 1016; stringent sets G=30.34,
P=1.26 105).
Compared with the positive training dataset, there was
no signiﬁcant difference in the location of sites relative to
genes for the stringent set predicted by the combined-
evidence model (G=8.06, 5 df, P=0.15), but there
were signiﬁcant differences for the other comparisons
for both the combined-evidence model (large set
G=70.20, P=9.3 1014; intermediate set G=40.29,
P=1.3 107) and for the sequence-only model (large
set G=23.56, P=2.64 104; intermediate set
G=18.19, P=2.72 103; stringent set G=23.04,
P=3.31 104).
At the level of individual regions, the differences
between the combined-evidence model and the sequence-
only model were signiﬁcant in the large set for the
intragenic, TSS, 5 kb downstream, 5–25 kb upstream and
intergenic regions (Supplementary Table S9). In the inter-
mediate and stringent sets, the differences were signiﬁ-
cant for the intragenic, TSS and intergenic regions
(Supplementary Table S9).
In summary, both models made predictions that were
not randomly placed relative to genes. The combined-
evidence and sequence-only models made different predic-
tions, showing that the models were not equivalent. At the
stringent cutoff, the sites predicted by the combined-
evidence model were not signiﬁcantly different from
those in the positive training dataset, whereas those pre-
dicted by the sequence-only model did differ from the sites
in the positive training dataset. These results are consistent
with both models working to some extent, and the
combined-evidence model making better predictions than
the sequence-only model.
Functional annotation of genome-wide predictions
To test whether the genes identiﬁed by the combined-
evidence model have functions commonly associated
with p53, we tested the intermediate sets of predictions
for enrichment in relevant GO biological process and
KEGG pathway terms. For the combined-evidence
model, there was an enrichment for biological process
terms linked to cell death and metabolism (Figure 5;
Supplementary Table S10) and an enrichment for
KEGG pathway terms linked to cancer, including the
speciﬁc category ‘p53 signaling pathway’ (Figure 6;
Supplementary Table S11). In contrast, the top biological
process terms for the sequence-only model did not include
‘regulation of apoptosis’, ‘regulation of cell death’ or
‘regulation of programmed cell death’ (Figure 7;
Supplementary Table S12). Instead, the top biological
process terms were linked to neural differentiation. The
KEGG pathways highlighted by the sequence-only
model did include ‘p53 signaling pathway’ but did not
include the other cancer pathways identiﬁed by the
Table 2. ChIP-PET sites in the test set predicted to be p53 binding sites by the sequence-only and combined-evidence models
Number of
tags per PET
cluster
Total number
of PET
clusters
Number of
PET clusters
not used for
training
Sequence-only model Combined-evidence model
Large set Intermediate
set
Stringent
set
Large set Intermediate
set
Stringent
set
>2 327 163 112 (68.71%) 62 (38.04%) 19 (11.66%) 106 (65.03%) 67 (41.10%) 25 (15.34%)
>4 106 49 40 (81.63%) 30 (61.22%) 13 (26.53%) 37 (75.51%) 26 (53.06%) 13 (26.53%)
>7 28 12 11 (91.67%) 9 (75.00%) 7 (58.33%) 9 (75.00%) 7 (58.33%) 3 (25.00%)
>10 6 3 3 (100.00%) 1 (33.33%)(2) 1 (33.33%)(2) 3 (100.00%) 3 (100.00%)(1,2,3) 1 (33.33%)(2)
>11 5 2 2 (100.00%) 1 (50.00%)(2) 1 (50.00%)(2) 2 (100.00%) 2 (100.00%)(2,3) 1 (50.00%)(2)
>12 3 1 1 (100.00%) 0 (0%) 0 (0%) 1 (100.00%) 1 (100.00%)(3) 0 (0%)
The number and fraction of sites identiﬁed by each model are given for each level of ChIP-PET stringency (i.e. minimum number of tags per PET
cluster). Counts are given with percentages in parentheses. For a given set size, where the fraction of sites predicted by the combined-evidence model
differs signiﬁcantly from that predicted by the sequence-only model (exact binomial test, P< 0.05), the count is given in bold font for the model
retrieving the largest fraction of the ChIP-PET sites. Signiﬁcantly different fractions were observed for the sets with >7 (stringent set, P=0.04), >10
(intermediate set, P=0.04) and >12 (intermediate set, P< 2.20 1016) tags. No tests were signiﬁcant after discounting a comparison with zero at
PET> 12 and after correction for multiple testing. Superscripts refer to speciﬁc PET clusters with >10 tags that are described in Supplementary
Table S5.
Table 1. ChIP-on-chip sites in the test set predicted to be p53
binding sites by the sequence-only and combined-evidence models
Model Large set Intermediate set Stringent set
Combined-evidence 330 (42.47 %) 147 (18.92 %) 35 (4.50 %)
Sequence-only 307 (39.51 %) 93 (11.97 %) 14 (1.80 %)
Among the 1545 ChIP-on-chip sites (26), 777 were used as a test set.
Counts are given with percentages in parentheses. The fraction of sites
predicted by the two models was signiﬁcantly different for the inter-
mediate (exact binomial test, P=2.62 108) and stringent (exact
binomial test, P=2.01 106) sets.
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combined-evidence model (Figure 8; Supplementary Table
S13). We conclude that, compared with the sequence-only
model, the combined-evidence model identiﬁes genes that
are more likely to be genuine p53 target genes.
Gene set enrichment analysis
If our predictions identify important p53 binding sites, the
expression of neighboring genes should change following
p53 activation. To test this, we analyzed gene expression
data from HCT116 colon cancer cells before and after p53
activation with 5FU. We ranked genes by strength of in-
duction or repression after p53 activation, then asked
whether genes near predicted p53 binding sites were
overrepresented near the beginning or end of the ranked
list. We used GSEA to quantify the results. To gain insight
into the performance of the models, we ranked the predic-
tions by logit or bit score, then performed GSEA for pro-
gressively increasing numbers of predictions. In GSEA
terminology, the binding site predictions would be called
‘gene sets’. For computational reasons, we increased the
size of the gene sets in steps of 100. The combined-
evidence predictions showed extremely signiﬁcant enrich-
ment for all gene sets except the ﬁrst (Figure 9, solid black
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Figure 4. Location of p53 binding sites predicted by the combined-evidence model relative to genes. The outer rings describe the predictions; the
inner rings describe the distribution over the entire genome. Signiﬁcantly enriched or under-represented regions (G test, P< 0.05) are marked with an
asterisk. Combined-evidence model: (A) large set, (B) intermediate set and (C) stringent set. Sequence-only model: (D) large set, (E) intermediate set
and (F) stringent set.
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Figure 5. Functional enrichment (P< 105) of ‘GO FAT’ terms for
biological process for the intermediate set predicted by the combined-
evidence model. In all, 2457 genes were associated with GO terms of
biological process. The order of the displayed GO terms is from least
signiﬁcant (top) to most signiﬁcant (bottom). The most signiﬁcant term
was ‘regulation of cell death’.
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line), whereas the sequence-only predictions showed no
enrichment (Figure 9, solid gray line; Supplementary
Figure S1). Interestingly, the result was only signiﬁcant
for gene induction by p53 (Figure 9, solid black line);
there was no enrichment for binding site predictions
among genes repressed by p53 (Figure 9, dotted black
line). A Mann–Whitney test of median evidence of differ-
ential expression conﬁrmed that the predictions for the
large prediction sets used above were different for the
combined-evidence and sequence-only models
(W=16192384, P=1.33 104). We conclude that the
combined-evidence model is vastly better than the
sequence-only model at identifying functionally
important p53 binding sites.
DISCUSSION
The main conclusion from this study is that inclusion of
histone modiﬁcation and spacer data in PWM-based
models greatly improves the prediction of functionally im-
portant p53 binding sites. Interestingly, the improvement
was barely signiﬁcant in conventional ChIP assays of
DNA binding, but stood out clearly in assays for func-
tionally important differences.
The ﬁrst criterion we used to test the quality of our
genome-wide predictions was the fraction of known
binding sites we could predict. Our initial expectation
was that the fraction would be higher for the model
including modiﬁcation and spacer data, but this was not
borne out by experiment. Given the large differences seen
in the genomic location and GSEA analyses, it may seem
paradoxical that the fraction of sites we could predict
should be so similar for the combined-evidence and
sequence-only models. If we had used only a measure of
sensitivity, the similarity could have been explained by the
PWM ﬁnding the same true positives under both models,
from which the combined-evidence model then eliminated
some false positives. Because true positives and negatives
are not known on a genome-wide scale, we compared the
models at equal, ﬁxed numbers of sites. In this setting,
sensitivity plays off directly against speciﬁcity. If the
number of true positives is constant under this constraint,
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Figure 9. GSEA for p53 activation by 5FU in HCT116 colon cancer
cells. Maximum (solid lines) and minimum (dashed lines) Z scores are
shown for the combined-evidence model (black) and sequence-only
model (gray). The Z score is positive when genes are induced and
negative when they are repressed. The Z scores were obtained by per-
mutations of the ranking of the HCT116 gene induction list.
Theoretical P=1 – 5 1015, 0.995, 0.975, 0.025, 0.005 and
5 1015 limits for a standard normal distribution are indicated
(dotted gray lines). The x-axis shows the number of genes included in
the gene list.
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Figure 6. KEGG pathway enrichment (P< 0.05) for the intermediate
set predicted by the combined-evidence model. In all, 1037 genes were
associated with the pathway terms. The most signiﬁcant term was
‘pathways in cancer’.
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Figure 8. KEGG pathway enrichment (P< 0.05) for the intermediate
set predicted by the sequence-only model. In all, 897 genes were
associated with the pathway terms. The most signiﬁcant term was
‘type II diabetes mellitus’.
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Figure 7. Functional enrichment (P< 105) of ‘GO FAT’ terms for
biological process for the intermediate set predicted by the sequence-
only model. In all, 2256 genes were associated with GO terms of
biological process. The most signiﬁcant term was ‘axon guidance’.
5590 Nucleic Acids Research, 2013, Vol. 41, No. 11
 at St A
ndrew
s U
niversity Library on July 30, 2013
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
we can infer that the number of false positives has not
shown the expected decrease under the combined-
evidence model. We suggest that the answer to this con-
undrum is that the combined-evidence model led to the
identiﬁcation of functionally important sites from within a
pool of equally plausible sites deﬁned by the essentially
biophysical criteria of PWM or ChIP. If correct, this
interpretation has two interesting implications: ﬁrst, the
avalanche of chromatin modiﬁcation data now entering
the databases will improve the prediction of functionally
important binding sites over and above what can be
achieved by ChIP for the factors themselves; and
second, many sites identiﬁed by ChIP are functionally
unimportant.
The ﬁrst point is underscored by results from several
other groups. Ernst et al. (22) combined a general
binding preference, based on a variety of features
relevant to transcription factor binding, with a subsequent
PWM step. This is an active ﬁeld of research where new
modiﬁcations are regularly identiﬁed and assigned to roles
in transcriptional regulation, notably by the international
consortium working on the ENCODE project (50). For
example, H3 lysine 27 acetylation (H3K27ac) has recently
been shown to mark enhancers (51–54). It is particularly
useful to distinguish active enhancers, marked by
H3K27ac and H3K4me1, from inactive enhancers,
marked only by H3K4me1 (51). The fact that our model
gave H3K4me3 a positive coefﬁcient in one cell strain and
a negative coefﬁcient in another may indicate that pro-
moters that are differentially active between the two cell
types are enriched in functional p53 sites. The higher mag-
nitude of the negative coefﬁcient is not surprising because
this particular mark is found both in enhancers, where it
should have a positive coefﬁcient, and at TSSs, where in
most cases there is no p53 binding and the coefﬁcient
should be negative. This type of consideration highlights
the importance of incorporating biological insights into
future models and hints at the great potential of the tech-
nique as more marks are identiﬁed and their signiﬁcance is
understood. The strength of approaches that take into
account chromatin state is that they can narrow down
the regions where functionally important binding occurs.
Their weakness is that each modiﬁcation dataset is unique
to a particular cell line or tissue. Hence, they will be most
informative when trying to predict the binding of a tran-
scription factor in a cell line that has already been
characterized epigenetically. Conversely, the sites pre-
dicted by our sequence-only model presumably contain a
substantial number of genuine binding sites that are only
functional, and so marked, in cell lines or tissues that
differ substantially from the ones we used to train the
model. This may partly explain the implication suggested
above, that ChIP does not deﬁne functional sites. This
should come as no great surprise because it is well
recognized that isolated binding of transcription factors
activates transcription poorly; this is the reason why
luciferase assays are normally performed with highly
multimerized sites. For example, the classic PG13-luc
vector contains 39 decameric p53 binding sites (55). To
create a functional enhancer, a group of transcription
factors normally collaborates to establish a state
permissive for transactivation of nearby genes. The chro-
matin modiﬁcations used in our model are both a cause
and a consequence of the efforts of these transcription
factors. A more fundamental approach would be to
identify the clusters of binding sites that establish the chro-
matin modiﬁcations. Smeenk et al. (27) performed this
type of analysis on their experimentally deﬁned p53
binding sites and identiﬁed enrichment for the REs
of eight transcription factors: Kru¨ppel-like factors,
Sp1/Sp3, basic helix-loop-helix proteins, AP1, AP2,
MZF1, CP2 and ETS2. It remains to be seen whether
combinations of sequence-speciﬁc transcription factors
can replace chromatin modiﬁcation data to identify func-
tionally important binding sites. The vocabulary of chro-
matin modiﬁcation is rich but far smaller than that of
transcription factors, so it is easier to generate comprehen-
sive maps of chromatin modiﬁcation than of transcription
factor binding, a situation that will persist at least into the
near future. A more general problem with models based
purely on transcription factor PWMs is that chromatin
modiﬁcations can facilitate or block transcription factor
binding. Because chromatin state captures essential infor-
mation about cell identity, it is unrealistic to expect tran-
scription factors to behave correctly without providing
information about cell identity. This could take several
forms but the only practical way to access it at present
is through epigenetic marks such as histone modiﬁcation
data.
The number of potential binding sites is far greater than
the number of genes. For this reason, scientists accus-
tomed to thinking in terms of genes commonly underesti-
mate the difﬁculty of identifying transcription factor
binding sites: there are roughly 106-fold more potential
binding sites than genes. Viewed from this perspective,
our estimate that we would require 106 predictions to
identify 90% of the ChIP-PET sites is less shocking.
That said, one obvious reason for a model to fail is the
use of the wrong PWM. This typically occurs when a tran-
scription factor binds to DNA indirectly; in this case, the
model should use the PWM for the factors directly con-
tacting the DNA. A long standing puzzle in genome-wide
gene expression studies has been the ﬁnding that activa-
tion of a single transcription factor leads almost invariably
to both induction and repression of target genes,
commonly in almost equal numbers. There is no mechan-
istic difﬁculty in explaining this based on the presence of
other factors at enhancers, but a simpler explanation is
that many of the changes seen may be indirect. Our
GSEA data point to this being the case for p53: there is
highly signiﬁcant enrichment for predicted binding
sites near genes showing increased expression but no
enrichment at all for sites near repressed genes. These
data indicate that when p53 binds directly to DNA, it
functions overwhelmingly as a transcriptional activator.
Given the experimentally proven examples of direct
repression (reviewed in 2), it is conceivable that training
the linear model with repressive chromatin marks would
have allowed us to identify enrichment for functionally
important p53 binding sites near repressed genes.
In summary, we have shown that models incorporating
histone modiﬁcation and decamer spacing information
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predict p53 binding scarcely better than models that
include only PWM information. We suggest that this is
because ChIP and PWMs are at heart biophysical
measures of protein–DNA binding. Where we see large
and highly signiﬁcant differences in the binding sites
selected by combined-evidence and sequence-only models
is in the number of functionally important sites. Because
this is the information biologists are most interested in, we
conclude that the approach is worthwhile and should be
further developed as more chromatin modiﬁcation data
become available. We expect the approach to be useful
with a wide range of transcription factors, not just p53,
and with genomes other than the human genome.
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